Apatinib for the Elderly Advanced Gastric Cancer

Sponsor
Affiliated Hospital of Qinghai University
Study ID
NCT03104283
Phase
PHASE2
Status
Completed

Conditions

Eligibility Criteria

Sex
ALL
Age
60 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • Apatinib — DRUG
    take apatinib orally until disease progression or appearance of unbearable toxicity

Study Details

The purpose of our study is to assess the efficacy and safety of apatinib in elderly advanced gastric cancer patients, and to find the relationship between the expression of VEGFR-2 and efficacy of apatinib treatment.

Key Dates

Start date
Jun 5, 2017
Status verified
Mar 2022
Primary completion
Dec 1, 2019
Completion
Jun 2, 2020

Study Design

Enrollment
48 participants (actual)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: Apatinib Group
    take apatinib orally (500mg/d or 250mg/d, once a day, continuously )

Primary Outcome Measure

Progression-free survival (PFS) [ Time Frame: 1 year ]

Related Studies